We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.07B
AUM Growth
-$1.75B
Cap. Flow
-$771M
Cap. Flow %
-72.36%
Top 10 Hldgs %
79.25%
Holding
36
New
4
Increased
1
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$42.6M
2
MRK icon
Merck
MRK
+$39.7M
3
UNH icon
UnitedHealth
UNH
+$38.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.7M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.89M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$121M
2
HUM icon
Humana
HUM
+$106M
3
BAX icon
Baxter International
BAX
+$87.9M
4
CVS icon
CVS Health
CVS
+$78.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 67.39%
2 Miscellaneous 32.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$73.7B
– –
-200,000
Closed -$65.8M
GMAB icon
27
Genmab
GMAB
$20.4B
– –
-50,000
Closed -$979K
GPCR icon
28
Structure Therapeutics
GPCR
$3.38B
– –
-300,000
Closed -$5.19M
IONS icon
29
Ionis Pharmaceuticals
IONS
$10.1B
– –
-725,000
Closed -$21.9M
MLTX icon
30
MoonLake Immunotherapeutics
MLTX
$1.28B
– –
-441,000
Closed -$17.2M
PFE icon
31
CALL
Pfizer
PFE
$159B
– –
-6,800,000
Closed -$172M
PTCT icon
32
PTC Therapeutics
PTCT
$5.85B
– –
-1,500,000
Closed -$76.4M
QGEN icon
33
Qiagen
QGEN
$8.9B
– –
-1,400,000
Closed -$56.2M
SRPT icon
34
Sarepta Therapeutics
SRPT
$2.2B
– –
-800,000
Closed -$51.1M
TXG icon
35
10x Genomics
TXG
$8.02B
– –
-1,000,000
Closed -$8.73M
XBI icon
36
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-2,000,000
Closed -$162M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Camber Capital Management held 36 positions worth $1.07B, down 62% from $2.81B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Camber Capital Management withdrew a net $771M in Q2 2025, closing 11 positions and reducing 17 holdings. Its most notable exit was PTC Therapeutics, an estimated $76.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 57% a quarter earlier, followed by Miscellaneous.

Against the trend, Camber Capital Management opened a new position in Icon worth $43.6M.

  • Camber Capital Management's largest Q2 2025 buy was Icon: 300,000 shares worth $43.6M.
  • Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2025, an estimated $5.89M increase.
  • Camber Capital Management's biggest Q2 2025 reduction was Zimmer Biomet, cutting an estimated $121M.
  • Camber Capital Management fully exited PTC Therapeutics in Q2 2025, selling an estimated $76.4M.
  • Camber Capital Management's ten largest holdings make up 79% of its $1.07B portfolio in Q2 2025.
  • Camber Capital Management opened 4 new positions and closed 11 in Q2 2025.
  • Camber Capital Management's portfolio value fell 62% quarter-over-quarter to $1.07B.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.